المؤلفون: С. В. Масолитин, Денис Николаевич Проценко, И. Н. Тюрин, О. А. Мамонтова, М. А. Магомедов, Т. Г. Ким, Л. А. Гришина, А. В. Яралян, А. Ю. Попов, Е. Ю. Калинин

المصدر: Вестник интенсивной терапии, Iss 4 (2022)

مصطلحات موضوعية: панкреатит, гемоперфузия, гемофильтрация, непрерывная заместительная почечная терапия, инфузионная терапия, транспульмональная термодилюция, Medical emergencies. Critical care. Intensive care. First aid, RC86-88.9

وصف الملف: electronic resource

Relation: https://intensive-care.ru/index.php/acc/article/view/319; https://doaj.org/toc/1726-9806; https://doaj.org/toc/1818-474X

URL الوصول: https://doaj.org/article/95cb0e3e224946dab344f2884dd8a0db

المؤلفون: Сергей Викторович Масолитин, Д. Н. Проценко, И. Н. Тюрин, О. А. Мамонтова, М. А. Магомедов, Т. Г. Ким, А. Ю. Попов

المصدر: Вестник интенсивной терапии, Iss 2 (2022)

مصطلحات موضوعية: миоглобин, больничная смертность, гемодиафильтрация, гемоперфузия, острая почечная травма, интенсивная терапия, Medical emergencies. Critical care. Intensive care. First aid, RC86-88.9

وصف الملف: electronic resource

Relation: https://intensive-care.ru/index.php/acc/article/view/292; https://doaj.org/toc/1726-9806; https://doaj.org/toc/1818-474X

URL الوصول: https://doaj.org/article/52d7ac00251845cc8f341b0fd869bc26

المؤلفون: S. V. Masolitin, D. N. Protsenko, I. N. Tyurin, O. A. Mamontova, M. A. Magomedov, С. В. Масолитин, Д. Н. Проценко, И. Н. Тюрин, О. А. Мамонтова, М. А. Магомедов

المصدر: General Reanimatology; Том 18, № 3 (2022); 59-68 ; Общая реаниматология; Том 18, № 3 (2022); 59-68 ; 2411-7110 ; 1813-9779

مصطلحات موضوعية: обзор литературы, acute kidney injury, renal replacement therapy, plasma exchange, selective hemoperfusion, review, острое повреждение почек, заместительная почечная терапия, плазмообмен, селективная гемосорбция

وصف الملف: application/pdf

Relation: https://www.reanimatology.com/rmt/article/view/2379/1761; https://www.reanimatology.com/rmt/article/view/2379/1762; Saverymuthu A., Teo R., Zain J.M., Cheah S.K., Yusof A.M., Rahman R.A. Acute kidney injury following rhabdomyolysis in critically ill patients. J Crit Care Med (Targu Mures). 2021; 7 (4): 267–271. DOI:10.2478/jccm-2021-0025. PMID: 34934816.; Flynn Makic M.B. Rhabdomyolysis: recognizing risks. J Perianesth Nurs. 2019; 34 (6): 1282–1283. DOI:10.1016/j.jopan.2019.08.001. PMID: 31619324.; Kim H.W., Kim S., Ohn J.H., Kim N-H, Lee J., Kim E.S., Lim Y., Cho J.H., Park H.S., Ryu J., Kim S.W. Role of bicarbonate and volume therapy in the prevention of acute kidney injury in rhabdomyolysis: a retrospective propensity score-matched cohort study. Kidney Res Clin Pract. 2021 Dec 2. Online ahead of print. DOI:10.23876/j.krcp.21.093. PMID: 34974654.; Riccardi J., Fredericks C.J., Callcut R.A. Trauma and COVID-induced severe rhabdomyolysis. Am Surg. 2022; 88 (5): 1003–1005. DOI:10.1177/00031348211063569. PMID: 34957839.; Stahl K., Rastelli E., Schoser B. A systematic review on the definition of rhabdomyolysis. J Neurol. 2020; 267 (4): 877–882. DOI:10.1007/s00415-019-09185-4. PMID: 30617905.; Albaba I., Chopra A., Al-Tarbsheh A.H., Feustel P.J., Mustafa M., Oweis J., Parimi S,A., Santelises Robledo F.M., Mehta S. Incidence, risk factors, and outcomes of rhabdomyolysis in hospitalized patients with COVID-19 infection. Cureus. 2021; 13 (11): e19802. DOI:10.7759/cureus.19802. PMID: 34956789.; Paternostro C., Gopp L., Tomschik M., Krenn M., Weng R., Bointner K., Jäger F., Zulehner G., Rath J., Berger T., Zimprich F., Cetin H. Incidence and clinical spectrum of rhabdomyolysis in general neurology: a retrospective cohort study. Neuromuscul Disord. 2021; 31 (12): 1227–1234. DOI:10.1016/j.nmd.2021.09.012. PMID: 34711480.; Parish L.P., Cutshall T., Duhart B. Acute kidney injury and rhabdomyolysis due to ticagrelor and rosuvastatin. Nurse Pract. 2021; 46 (11): 12–16. DOI:10.1097/01.NPR.0000794540.96561.51. PMID: 34695045.; Somagutta M.R., Pagad S., Sridharan S., Nanthakumaran S., Arnold A.A., May V., Malik B.H. Role of bicarbonates and mannitol in rhabdomyolysis: a comprehensive review. Cureus. 2020; 12 (8): e9742. DOI:10.7759/cureus.9742. PMID: 32944457.; Osborn H., Grossman D., Kochhar S., Kanukuntla A., Kata P., Cheriyath P. A rare case of delayed onset multi-drug interaction resulting in rhabdomyolysis in a 66-year-old male. Cureus. 2021; 13 (11): e20035. DOI:10.7759/cureus.20035. PMID: 34987920.; Maheshwari M., Athiraman H. «Speedballing» to severe rhabdomyolysis and hemodialysis in a 27-year-old male. Cureus. 2021; 13 (12): e20667. DOI:10.7759/cureus.20667. PMID: 34976547.; Kodikara P., Walker R., Wilson S. Renal physiology and kidney injury during intense (CrossFit®) exercise. Intern Med J. 2021 Dec 22. Online ahead of print. DOI:10.1111/imj.15667. PMID: 34935262.; Wilson M.T., Reeder B.J. The peroxidatic activities of myoglobin and hemoglobin, their pathological consequences and possible medical interventions. Mol Aspects Med. 2022; 84: 101045. DOI:10.1016/j.mam.2021.101045. PMID: 34654576.; Sawhney J.S., Kasotakis G., Goldenberg A., Abramson S., Dodgion C., Patel N., Khan M., Como J.J. Management of rhabdomyolysis: a practice management guideline from the Eastern Association for the Surgery of Trauma. Am J Surg. 2021; S0002-9610 (21)00681-4. DOI:10.1016/j.amjsurg.2021.11.022. PMID: 34836603.; Hui W.F., Hon K.L., Lun K.S., Leung K.K.Y., Cheung W.L., Leung A.K.C. Successful treatment of rhabdomyolysis-associated acute kidney injury with haemoadsorption and continuous renal replacement therapy. Case Rep Pediatr. 2021; 2021: 2148024. DOI:10.1155/2021/2148024. PMID: 34646583.; Long B., Koyfman A., Gottlieb M. An evidence-based narrative review of the emergency department evaluation and management of rhabdomyolysis. Am J Emerg Med. 2019; 37 (3): 518–523. DOI:10.1016/j.ajem.2018.12.061. PMID: 30630682.; Lee G.X., Duong D.K. Rhabdomyolysis: evidence-based management in the emergency department. Emerg Med Pract. 2020; 22 (12): 1–20. PMID: 33211443.; Gupta N., Nusbaum J. Points & pearls: rhabdomyolysis: evidencebased management in the emergency department. Emerg Med Pract. 2020; 22 (Suppl 12): 1–2. PMID: 33259708.; Long B., Targonsky E., Koyfman A. Just the facts: diagnosis and management of rhabdomyolysis. CJEM. 2020; 22 (6): 745–748. DOI:10.1017/cem.2020.37. PMID: 32390586.; Ankawi G., Xie Y., Yang B., Xie Y., Xie P., Ronco C. What have we learned about the use of cytosorb adsorption columns? Blood Purif. 2019; 48 (3): 196–202. DOI:10.1159/000500013. PMID: 31039564.; Жарский С.Л., Слободянюк О.Н., Слободянюк С.Н. Рабдомиолиз, связанный с физической нагрузкой у лиц молодого возраста. Клиническая медицина. 2013; 3: 62–65.; Bagley W.H., Yang H., Shah K.H. Rhabdomyolysis. Intern Emerg Med. 2007; 2 (3): 210–218. DOI:10.1007/s11739-007-0060-8. PMID: 17909702.; Chavez L.O, Leon M., Einav S., Varon J. Beyond muscle destruction: a systematic review of rhabdomyolysis for clinical practice. Crit Care. 2016; 20 (1): 135. DOI:10.1186/s13054-016-1314-5. PMID: 27301374.; Bosch X., Poch E., Grau J.M. Rhabdomyolysis and acute kidney injury. N. Engl. J. Med. 2009; 361 (1): 62-72. DOI:10.1056/NEJMra0801327. PMID: 19571284.; Taxbro K., Kahlow H., Wulcan H., Fornarve A. Rhabdomyolysis and acute kidney injury in severe COVID-19 infection. BMJ Case Rep. 2020; 13 (9): 237616. DOI:10.1136/bcr-2020-237616. PMID: 32878841.; Warren J.D., Blumbergs P.C., Thompson P.D. Rhabdomyolysis: a review. Muscle Nerve. 2002: 332–347. DOI:10.1002/mus.10053. PMID: 11870710.; Panizo N., Rubio-Navarro A., Amaro-Villalobos J.M. Egido J., Moreno J.A. Molecular mechanisms and novel therapeutic approaches to rhabdomyolysis-induced acute kidney injury. Kidney Blood Press. Res. 2015; 40 (5): 520–532. DOI:10.1159/000368528. PMID: 26512883.; Petejova N., Martinek A. Acute kidney injury due to rhabdomyolysis and renal replacement therapy: a critical review. Crit. Care. 2014; 18 (3): 224. DOI:10.1186/cc13897. PMID: 25043142.; Kwiatkowska M., Chomicka I., Malyszko J. Rhabdomyoisis — induced acute kidney injury — an underestimated problem. Wiad. Lek. 2020; 73 (11): 2543–2548. PMID: 33454698.; Oshima Y. Characteristics of drug-associated rhabdomyolysis: analysis of 8,610 cases reported to the U.S. Food and Drug Administration. Intern. Med. 2011; 50 (8): 845–853. DOI:10.2169/internalmedicine.50.4484. PMID: 21498932.; Debelmas A., Benchetrit D., Galanaud D., Khonsari R.H. Case 251: nontraumatic drug-associated rhabdomyolysis of head and neck muscles. Radiology. 2018; 286 (3): 1088–1092. DOI:10.1148/radiol.2018152594. PMID: 29461948.; Nelson D.A., Deuster P.A., Carter R., Hill O.T., Woolcott V.L., Kurina L.M. Sickle cell trait, rhabdomyolysis, and mortality among U.S. army soldiers. N. Engl. J. Med. 2016; 375 (5): 435–442. DOI:10.1056/NEJMoa1516257. PMID: 27518662.; Gordon W.T., Talbot M., Shero J.C., Osier C.J., Johnson A.E., Balsamo L.H., Stockinger Z.T. Acute extremity compartment syndrome and the role of fasciotomy in extremity war wounds. Mil Med. 2018; 183 (suppl_2): 108–111. DOI:10.1093/milmed/usy084. PMID: 30189076.; Rawson E.S., Clarkson P.M., Tarnopolsky M.A. Perspectives on exertional rhabdomyolysis. Sports Med. 2017; 47: 33–49. DOI:10.1007/s40279-017-0689-z. PMID: 28332112.; Meyer M., Sundaram S., Schafhalter-Zoppoth I. Exertional and crossfit-induced rhabdomyolysis. Clin J Sport Med. 2018; 28 (6): 92–94. DOI:10.1097/JSM.0000000000000480. PMID: 28727638.; Fernandes P.M., Davenport R.J. How to do it: investigate exertional rhabdomyolysis (or not). Pract Neurol. 2019; 19 (1): 43–48. DOI:10.1136/practneurol-2018-002008. PMID: 30305378.; Kaur H., Katyal N., Yelam A. Kumar K., Srivastava H., Govindarajan R. Malignant hyperthermia. Mo Med. 2019; 116 (2): 154–159. PMID: 31040503.; Yang C.W., Li S., Dong Y., Paliwal N., Wang Y. Epidemiology and the impact of acute kidney injury on outcomes in patients with rhabdomyolysis. J Clin Med. 2021; 10 (9): 1950. DOI:10.3390/jcm10091950. PMID: 34062839.; Хорошилов С.Е., Никулин А.В. Патогенез, диагностика и эфферентное лечение рабдомиолиза, осложненного острой почечной недостаточностью. Тверской медицинский журнал. 2017; 5: 45–51. eLIBRARY ID: 30022440.; Tehrani P. P., Malek H. Early detection of rhabdomyolysis-induced acute kidney injury through machine learning approaches. Arch Acad Emerg Med. 2021; 9 (1): 29. DOI:10.22037/aaem.v9i1.1059. PMID: 34027424.; Baeza-Trinidad R., Brea-Hernando A., Morera-Rodriguez S., BritoDiaz Y., Sanchez-Hernandez S., El Bikri L., Ramalle-Gomara E., Garcia-Alvarez J.L. Creatinine as predictor value of mortality and acute kidney injury in rhabdomyolysis. Intern Med J. 2015; 45 (11): 1173–1178. DOI:10.1111/imj.12815. PMID: 26010490.; Michelsen J., Cordtz J., Liboriussen L., Behzadi M.T., Ibsen M., Damholt M.B., Møller M.H., Wiis J. Prevention of rhabdomyolysis‐induced acute kidney injury — A DASAIM/DSIT clinical practice guideline. Acta Anaesthesiol Scand. 2019; 63 (5): 576–586. DOI:10.1111/aas.13308. PMID: 30644084.; Holt S., Moore K. Pathogenesis of renal failure in rhabdomyolysis: the role of myoglobin. Exp Nephrol. 2000; 8 (2): 72–76. DOI:10.1159/000020651. PMID: 10729745.; Kasaoka S., Todani M., Kaneko T., Kawamura Y., Oda Y., Tsuruta R., Maekawa T. Peak value of blood myoglobin predicts acute renal failure induced by rhabdomyolysis. J Crit Care. 2010; 25 (4): 601–604. DOI:10.1016/j.jcrc.2010.04.002. PMID: 20537502.; Zorova L.D., Pevzner I.B., Chupyrkina A.A., Zorov S.D., Silachev D.N., Plotnikov E.Y., Zorov D.B. The role of myoglobin degradation in nephrotoxicity after rhabdomyolysis. Chem Biol Interact. 2016; 256: 64–70. DOI:10.1016/j.cbi.2016.06.020. PMID: 27329933.; Ahmed M., Frederickson J., Khan K., Bashir K. Rhabdomyolysis after total abdominal hysterectomy requiring urgent hemodialysis due to hyperkalemia. Cureus. 2021; 13 (4): 14757. DOI:10.7759/cureus.14757. PMID: 34084681.; Chavez L.O., Leon M., Einav S., Varon J. Beyond muscle destruction: a systematic review of rhabdomyolysis for clinical practice. Crit Care. 2016; 20 (1): 135. DOI:10.1186/s13054-016-1314-5. PMID: 27301374.; Buitendag J.J.P., Patel M.Q., Variawa S., Fichardt J., Mostert B., Goliath A., Clarke D.L., Oosthuizen G.V. Venous bicarbonate and creatine kinase as diagnostic and prognostic tools in the setting of acute traumatic rhabdomyolysis. S Afr Med J. 2021; 111 (4): 333–337. DOI:10.7196/SAMJ.2021.v111i4.14915. PMID: 33944766.; Ahmad S., Anees M., Elahi I., Fazal-E-Mateen. Rhabdomyolysis leading to acute kidney injury. J Coll Physicians Surg Pak. 2021; 31 (2): 235–237.DOI:10.29271/jcpsp.2021.02.235. PMID: 33645199.; Vanholder R., Sükrü Sever M., Lameire N. Kidney problems in disaster situations. Nephrol Ther. 2021; 17S: S27-36. DOI:10.1016/j.nephro.2020.02.009. PMID: 33910695.; Ronco C. Extracorporeal therapies in acute rhabdomyolysis and myoglobin clearance. Crit Care. 2005; 9 (2): 141–142. DOI:10.1186/cc3055. PMID: 15774064.; Donati G., Cappuccilli M., Di Filippo F., Nicoletti S., Ruggeri M., Scrivo A., Angeletti A., La Manna G. The use of supra-hemodiafiltration in traumatic rhabdomyolysis and acute kidney injury: a case report. Case Rep Nephrol Dial. 2021; 11 (1): 26–35. DOI:10.1159/000507424. PMID: 33708797.; Guzman N., Podoll A.S., Bell C.S., Finkel K.W. Myoglobin removal using high-volume high-flux hemofiltration in patients with oliguric acute kidney injury. Blood Purif. 2013; 36 (2): 107–111. DOI:10.1159/000354727. PMID: 24080745.; Masakane I., Sakurai K. Current approaches to middle molecule removal: room for innovation. Nephrol Dial Transplant. 2018; 33 (3): iii12–iii21. DOI:10.1093/ndt/gfy224. PMID: 30281129.; Heyne N., Guthoff M., Krieger J., Haap M., Häring H-U. High cut-off renal replacement therapy for removal of myoglobin in severe rhabdomyolysis and acute kidney injury: a case series. Nephron Clin Pract. 2012; 121 (3–4): 159–164. DOI:10.1159/000343564. PMID: 23327834.; Naka T., Jones D., Baldwin I., Fealy N., Bates S., Goehl H., Morgera S., Neumayer H.H., Bellomo R. Myoglobin clearance by super highflux hemofiltration in a case of severe rhabdomyolysis: a case report. Crit Care. 2005; 9 (2): R90–95. DOI:10.1186/cc3034. PMID: 15774055.; Zhang L., Kang Y., Fu P., Cao Y., Shi Y., Liu F., Hu Z., Su B, Tang W., Qin W. Myoglobin clearance by continuous venous-venous haemofiltration in rhabdomyolysis with acute kidney injury: a case series. Injury. 2012; 43 (5): 619–623. DOI:10.1016/j.injury.2010.08.031. PMID: 20843513.; Weidhase L., Haussig E., Haussig S., Kaiser T., de Fallois J., Petros S. Middle molecule clearance with high cut-off dialyzer versus highflux dialyzer using continuous veno-venous hemodialysis with regional citrate anticoagulation: a prospective randomized controlled trial. PLoS One. 2019; 14 (4): 0215823. DOI:10.1371/journal.pone.0215823. PMID: 31026303.; Бельских А.Н., Захаров М.В., Марухов А.В., Корольков О.А. Сравнение эффективности методов экстракорпоральной детоксикации при лечении постнагрузочного рабдомиолиза, осложненного острым почечным повреждением. Военно-медицинский журнал. 2019; 340 (6): 49–54. DOI:10.17816/RMMJ81896.; Premru V., Kovač J., Buturović-Ponikvar J., Ponikvar R. Some kinetic considerations in high cut-off hemodiafiltration for acute myoglobinuric renal failure. Ther Apher Dial. 2013: 17 (4): 396–401. DOI:10.1111/1744-9987.12085. PMID: 23931878.; Albert C., Haase M., Bellomo R., Mertens P.R. High cut-off and highflux membrane haemodialysis in a patient with rhabdomyolysisassociated acute kidney injury. Crit Care Resusc. 2012; 14 (2): 159–162. PMID: 22697626.; Weidhase L., de Fallois J., Haußig E., Kaiser T., Mende M., Petros S. Myoglobin clearance with continuous veno-venous hemodialysis using high cutoff dialyzer versus continuous veno-venous hemodiafiltration using high-flux dialyzer: a prospective randomized controlled trial. Crit Care. 2020; 24 (1): 644. DOI:10.1186/s13054020-03366-8. PMID: 33176824.; Gubensek J., Persic V., Jerman A., Premru V. Extracorporeal myoglobin removal in severe rhabdomyolysis with high cut-off membranes-intermittent dialysis achieves much greater clearances than continuous methods. Crit Care. 2021; 25 (1): 97. DOI:10.1186/s13054-021-03531-7. PMID: 3375039.; Конева О.А., Руденко М.Ю., Ганич Э.С. Случай успешного раннего применения плазмафереза при рабдомиолизе. Нефрология и диализ. 2001; 3 (2): 197.; Завертайло Л.Л., Мальков О.А. Случай успешного лечения синдрома позиционного сдавления, осложнившегося паренхиматозной ОПН, сочетанным применением эфферентных методик НПЗП и плазмафереза (клиническое наблюдение). Интенсивная терапия. 2005; 1: 3–9.; Swaroop R., Zabaneh R., Parimoo N. Plasmapheresis in a patient with rhabdomyolysis: a case report. Cases J. 2009; 2: 8138. DOI:10.4076/1757-1626-2-8138. PMID: 19918458.; Теплова Н.Н. Рабдомиолиз в клинической практике. Вятский медицинский вестник. 2016; 52 (4): 37–45. eLIBRARY ID: 28789214.; Szczepiorkowski Z.M., Winters J.L., Bandarenko N., Kim H.C., Linenberger M.L., Marques M.B., Sarode R., Schwartz J., Weinstein R., Shaz B.H. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher. 2010; 25 (3): 83–177. DOI:10.1002/jca.20240. PMID: 20568098.; Yang K.C., Fang C.C., Su T.C., Lee Y.T. Treatment of fibrate-induced rhabdomyolysis with plasma exchange in ESRD. Am J Kidney Dis. 2005; 45 (3): 57–60. DOI:10.1053/j.ajkd.2004.12.003. PMID: 15754265.; Федорова А.А., Кутепов Д.Е., Зубарев А.В., Пасечник И.Н., Хабарина Н.В. Рабдомиолиз: что нового в диагностике и лечении? Кремлевская медицина. Клинический вестник. 2020; 2: 102–109. DOI:10.26269/4n94-0746.; Ogawa T., Yoshino H., Sasaki Y., Kanayama Y., Sano T., Kogure Y., Kanozawa K., Hasegawa H. Our approaches to selective plasma exchange. Contrib Nephrol. 2018; 196: 194–199. DOI:10.1159/000485722. PMID: 30041227.; Taniguchi K., Miyahara T. EVACURETM — membrane plasma separator with unique permeability properties. Med Sci Digest. 2002; 28 (6): 29–33.; Li M., Xue J., Liu J., Kuang D., Gu Y., Lin S. Efficacy of cytokine removal by plasmadiafiltration using a selective plasma separator: in vitro sepsis model. Ther Apher Dial. 2011; 15 (1): 98–108. DOI:10.1111/j.1744-9987.2010.00850.x. PMID: 21272259.; Tan E.X., Wang M.X., Pang J., Lee G.H. Plasma exchange in patients with acute and acute-on-chronic liver failure: a systematic review. World J Gastroenterol. 2020; 26 (2): 219–245. DOI:10.3748/wjg.v26.i2.219. PMID: 31988586.; Bonavia A., Groff A., Karamchandani K., Singbartl K. Clinical utility of extracorporeal cytokine hemoadsorption therapy: a literature review. Blood Purif. 2018; 46 (4): 337–349.DOI:10.1159/000492379. PMID: 30176653.; Poli E.C., Rimmelé T., Schneider A.G. Hemoadsorption with CytoSorb®. Intensive Care Med. 2019; 45 (2): 236–239. DOI:10.1007/s00134-018-5464-6. PMID: 30446798.; Zuccari S., Damiani E., Domizi R., Scorcella C., D’Arezzo M., Carsetti A., Pantanetti S., Vannicola S., Casarotta E., Ranghino A., Donati A., Adrario E. Changes in cytokines, haemodynamics and microcirculation in patients with sepsis/septic shock undergoing continuous renal replacement therapy and blood purification with CytoSorb. Blood Purif. 2020; 49 (1–2): 107–113. DOI:10.1159/000502540. PMID: 31434083.; Dilken O., Ince C., van der Hoven B., Thijsse S., Ormskerk P., de Geus H.R.H. Successful reduction of creatine kinase and myoglobin levels in severe rhabdomyolysis using extracorporeal blood purification (CytoSorb®). Blood Purif. 2020; 49 (6): 743–747. DOI:10.1159/000505899. PMID: 32114569.; Padiyar S., Deokar A., Birajdar S., Walawalkar A., Doshi H. Cytosorb for management of acute kidney injury due to rhabdomyolysis in a child. Indian Pediatr. 2019; 56 (11): 974–976. PMID: 31729332.; Lang C.N., Sommer M.J., Neukamm M.A., Staudacher D.L., Supady A., Bode C., Duerschmied D., Lother A. Use of the CytoSorb adsorption device in MDMA intoxication: a first-in-man application and in vitro study. Intensive Care Med Exp. 2020; 8 (1): 21. DOI:10.1186/s40635-020-00313-3. PMID: 32542550.; Scharf C., Liebchen U., Paal M., Irlbeck M., Zoller M., Schroeder I. Blood purification with a cytokine adsorber for the elimination of myoglobin in critically ill patients with severe rhabdomyolysis. Crit. Care. 2021; 25 (1): 41. DOI:10.1186/s13054-021-03468-x. PMID: 33509234.; https://www.reanimatology.com/rmt/article/view/2379

الاتاحة: https://www.reanimatology.com/rmt/article/view/2379
https://doi.org/10.15360/1813-9779-2022-3-59-68

المؤلفون: S. V. Masolitin, D. N. Protsenko, I. N. Tyurin, O. A. Mamontova, M. A. Magomedov, T. G. Kim, A. V. Yaralyan, С. В. Масолитин, Д. Н. Проценко, И. Н. Тюрин, О. А. Мамонтова, М. А. Магомедов, Т. Г. Ким, А. В. Яралян

المصدر: Messenger of ANESTHESIOLOGY AND RESUSCITATION; Том 19, № 1 (2022); 58-66 ; Вестник анестезиологии и реаниматологии; Том 19, № 1 (2022); 58-66 ; 2541-8653 ; 2078-5658

مصطلحات موضوعية: заместительная почечная терапия, selective hemoperfusion, acute kidney injury, renal replacement therapy, селективная гемоперфузия, острое повреждение почек

وصف الملف: application/pdf

Relation: https://www.vair-journal.com/jour/article/view/627/540; Жарский С. Л., Слободянюк О. Н., Слободянюк С. Н. Рабдомиолиз, связанный с физической нагрузкой у лиц молодого возраста // Клиническая медицина. ‒ 2013. – № 3. – С. 62–65.; Федорова А. А., Кутепов Д. Е., Зубарев А. В. и др. Рабдомиолиз: что нового в диагностике и лечении? // Кремлевская медицина. Клинический вестник. ‒ 2020. ‒ № 2. ‒ С. 102‒109.; Хорошилов С. Е. Детоксикация при критических состояниях: понимание научной проблемы в XXI веке (обзор) // Общая реаниматология. ‒ 2017. ‒ Т. 5, № 13. – С. 85–108; doi:10.15360/1813-9779-2017-5-85-108.; Хорошилов С. Е. Патогенез, диагностика и эфферентное лечение рабдомиолиза, осложненного острой почечной недостаточностью // Тверской медицинский журнал. ‒ 2017. ‒ № 5. ‒ С. 45‒51.; Bagley W. H., Yang H., Shah K. H. Rhabdomyolysis // Intern. Emerg. Med. – 2017. – Vol. 2, № 3. – Р. 210–218. DOI:10.1007/s11739-007-0060-8.; Bosch X., Poch E., Grau J. M. Rhabdomyolysis and acute kidney injury // N. Engl. J. Med. – 2009. – Vol. 361, № 1. – Р. 62–72. DOI:10.1056/NEJMra0801327.; Chatzizisis Y. S. et al. The syndrome of rhabdomyolysis: complications and treatment // Eur. J. Intern. Med. ‒ 2008. ‒ Vol. 19, № 8. ‒ Р. 568–574. DOI:10.1016/j.ejim. 200.06.037.; Cote D. R. et al. A “crush” course on rhabdomyolysis: risk stratification and clinical management update for the perioperative clinician // J. Anesth. ‒ 2020. ‒ Vol. 34, № 4. ‒ Р. 585–598. DOI:10.1007/s00540-020-02792-w.; Debelmas A., Benchetrit D., Galanaud D. et al. Case 251: nontraumatic drug-associated rhabdomyolysis of head and neck muscles // Radiology. – 2018. – Vol. 286, № 3. – Р. 1088–1092. DOI:10.1148/radiol.2018152594.; Donati G., Cappuccilli M., Di Filippo F. et al. The Use of supra-hemodiafiltration in traumatic rhabdomyolysis and acute kidney injury: A case report // Case Rep. Nephrol. Dial. ‒ 2021. ‒ Vol. 11, № 1. – Р. 26‒35. DOI:10.1159/000507424.; Kwiatkowska M., Chomicka I., Malyszko J. Rhabdomyolysis – induced acute kidney injury – an underestimated problem // Wiad. Lek. ‒ 2020. – Vol. 73, № 11. – Р. 2543–2548. DOI:10.36740/wlek202011137.; Lang C. N., Sommer M. J., Neukamm M. A. et al. Use of the CytoSorb adsorption device in MDMA intoxication: a first-in-man application and in vitro study // Intens. Care Med. Exp. ‒ 2020. ‒ Vol. 8, № 1. – Р. 21. DOI:10.1186/s40635-020-00313-3.; Masakane I., Sakurai K. Current approaches to middle molecule removal: room for innovation. Nephrol Dial Transplant, 2018. 33(suppl_3): iii12–iii21, DOI:10.1093/ndt/gfy224.; Oshima Y. Characteristics of drug-associated rhabdomyolysis: analysis of 8,610 cases reported to the U.S. Food and Drug Administration // Intern. Med. – 2011. – Vol. 50, № 8. – P. 845–853. DOI:10.2169/internalmedicine.50.4484.; Padiyar S., Deokar A., Birajdar S. et al. Cytosorb for management of acute kidney injury due to rhabdomyolysis in a child // Indian. Pediatr. ‒ 2019. ‒ Vol. 56, № 11. – Р. 974‒976. DOI:10.1007/s13312-019-1661-9.; Panizo N., Rubio-Navarro A., Amaro-Villalobos J. M. et al. Molecular mechanisms and novel therapeutic approaches to rhabdomyolysis-induced acute kidney injury // Kidney Blood Press. Res. – 2015. – Vol. 40, № 5. – Р. 520–532. DOI:10.1159/000368528.; Petejova N., Martinek A. Acute kidney injury due to rhabdomyolysis and renal replacement therapy: a critical review // Crit. Care. 2014. – Vol. 18, № 3. – Р. 224. DOI:10.1186/cc13897.; Ronco C. Extracorporeal therapies in acute rhabdomyolysis and myoglobin clearance // Crit. Care. 2005. ‒ Vol. 9, № 2. ‒ Р. 141–142. DOI:10.1186/cc3055.; Scharf C., Liebchen U., Paal M. et al. Blood purification with a cytokine adsorber for the elimination of myoglobin in critically ill patients with severe rhabdomyolysis // Crit. Care. ‒ Vol. 25, № 41 (2021). DOI:10.1186/s13054-021-03468-x.; Taxbro K., Kahlow H., Wulcan H., Fornarve A. Rhabdomyolysis and acute kidney injury in severe COVID-19 infection // BMJ Case Rep. ‒ 2020. – Vol. 13, № 9. – Р. 237616. DOI:10.1136/bcr-2020-237616.; https://www.vair-journal.com/jour/article/view/627

الاتاحة: https://www.vair-journal.com/jour/article/view/627
https://doi.org/10.21292/2078-5658-2022-19-1-58-66

المؤلفون: B. Z. Belotserkovskiy, E. B. Gelfand, A. O. Bykov, O. A. Mamontova, D. N. Protsenko, Б. З. Белоцерковский, Е. Б. Гельфанд, А. О. Быков, О. А. Мамонтова, Д. Н. Проценко

المصدر: Pelvic Surgery and Oncology; Том 9, № 4 (2019); 11-20 ; Тазовая хирургия и онкология; Том 9, № 4 (2019); 11-20 ; 2686-7435

مصطلحات موضوعية: анидулафунгин, intensive care unit, echinocandins, anidulafungin, отделение реанимации и интенсивной терапии, эхинокандины

وصف الملف: application/pdf

Relation: https://ok.abvpress.ru/jour/article/view/328/273; Petri M., Konig J., Moecke H. et al. Epidemiology of invasive mycosis in ICU patients: a prospective multicenter study in 435 non-neutropenic patients. Intensive Care Med 1997;23:317–25.; Vincent J., Rello J., Marshall J. et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009;302(21):2323–9.; Bougnoux M., Kac G., Aegerter P. et al. Candidemia and candiduria in critically ill patients admitted to intensive care units in France: incidence, molecular diversity, management, and outcome. Intensive Care Med 2008;34:292–9.; Kett D.H., Azoulay E., Echeverria P.M., Vincent J.L. Candida bloodstream infections in intensive care units: analysis of the extended prevalence of infection in intensive care unit study. Crit Care Med 2011;39:665–70.; Dimopoulos G., Ntziora F., Rachiotis G. et al. Candida albicans versus non-albicans intensive care unit-acquired bloodstream infections: differences in risk factors and outcome. Anesth Analg 2008;106:523–9.; Prowle J.R., Echeverri J.E., Ligabo E.V. et al. Acquired bloodstream infection in the intensive care unit: incidence and attributable mortality. Crit Care 2011;15:R100.; Blot S., Dimopoulos G., Rello J. et al. Is Candida really a threat in the ICU? Curr Opin Crit Care 2008;14:600–4.; Holley A., Dulhunty J., Blot S. et al. Temporal trends, risk factors and outcomes in albicans and non-albicans candidaemia: an international epidemiological study in four multidisciplinary intensive care units. Int J Antimicrob Agents 2009;33:554–7.; Kotwal A., Biswas D., Sharma J.P. et al. An observational study on the epidemiological and mycological profile of candidemia in ICU patients. Med Sci Monit 2011;17:CR663–8.; McKinnon P.S., Goff D.A., Kern J.W. et al. Temporal assessment of Candida risk factors in the surgical intensive care unit. Arch Surg 2001;136:1401–8.; Leon C., Alvarez-Lerma F., Ruiz-Santana S. et al. Fungal colonization and/or infection in non-neutropenic critically ill patients: results of the EPCAN observational study. Eur J Clin Microbiol Infect Dis 2009;28:233–42.; Eggimann P., Bille J., Marchetti O. Diagnosis of invasive candidiasis in the ICU. Ann Intensive Care 2011;1:37.; Яковлев С.В., Суворова М.П., Белобородов В.Б. и др. Распространенность и клиническое значение нозокомиальных инфекций в лечебных учреждениях России: исследование ЭРГИНИ. Антибиотики и химиотерапия 2016;(61):5–6.; Falagas M.E., Apostolou K.E., Pappas V.D. Attributable mortality of candidemia: a systematic review of matched cohort and case-control studies. Eur J Clin Microbiol Infect Dis 2006;25:419–25.; Gudlaugsson O., Gillespie S., Lee K. et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003;37:1172–7.; Arendrup M.C., Sulim S., Holm A. et al. Diagnostic issues, clinical characteristics, and outcomes for patients with fungemia. J Clin Microbiol 2011;49:3300–8.; Papon N., Courdavault V., Clastre M. et al. Emerging and emerged pathogenic Candida species: beyond the Candida albicans paradigm. PLoS Pathog 2013;9:e1003550.; Klimko N., Vasilyeva N., Chernenkaya T. et al. Invasive candidiasis in intensive care units: results of prospective multicenter study in Russia. ECCMID 2015.; Климко Н.Н., Рубинчик В.Е., Соболь М.М. и др. Результаты проспективного многоцентрового исследования применения анидулафунгина – ЭРА (Эраксис в Российской Федерации). Проблемы медицинской микологии 2018;20(3): 21–4.; Kullberg B.J., Verweij P.E., Akova M. et al. European expert opinion on the management of invasive candidiasis in adults. Clin Microbiol Infect 2011;17(Suppl 5):1–12.; Leroy O., Gangneux J.P., Montravers P. et al. Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005–2006). Crit Care Med 2009;37(5):1612–8.; Веселов А.В., Климко Н.Н., Кречикова О.И. и др. In vitro активность флуконазола и вориконазола в отношении более чем 10 000 штаммов дрожжей: результаты 5-летнего проспективного исследования ARTEMIS Disk в России. Клиническая микробиология и антимикробная химиотерапия 2008;10(4):345–54.; Morrell M., Fraser V.J., Kollef M.H. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005;49:3640–5.; Barnes R.A. Early diagnosis of fungal infection in immunocompromised patients. J Antimicrob Chemother 2008;61 (Suppl 1):i3–6.; McMullan R., Metwally L., Coyle P.V. et al. A prospective clinical trial of a realtime polymerase chain reaction assay for the diagnosis of candidemia in nonneutropenic, critically ill adults. Clin Infect Dis 2008;46:890–6.; Taur Y., Cohen N., Dubnow S. et al. Effect of antifungal therapy timing on mortality in cancer patients with candidemia. Antimicrob Agents Chemother 2010;54:184–90.; Zaragoza R., Peman J., Salavert M. et al. Multidisciplinary approach to the treatment of invasive fungal infections in adult patients. Prophylaxis, empirical, preemptive or targeted therapy, which is the best in the different hosts? Ther Clin Risk Manag 2008;4:1261–80.; Kanafani Z.A., Perfect J.R. Antimicrobial resistance: resistance to antifungal agents: mechanisms and clinical impact. Clin Infect Dis 2008;46:120–8.; Ellis M. New dosing strategies for liposomal amphotericin B in high-risk patients. Clin Microbiol Infect 2008;14(Suppl 4):55–64.; Playford E.G., Eggimann P., Calandra T. Antifungals in the ICU. Curr Opin Infect Dis 2008;21:610–9.; Pappas P.G., Kauffman C.A., Andes D.R. et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 2016;62(4):e1–50.; Cornely O., Bassetti M., Calandra T. et al. ESCMID guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect 2012;18(Suppl 7):19–37.; Moudgal V., Little T., Boikov D., Vazquez J.A. Multiechinocandin- and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis. Antimicrob Agents Chemother 2005;49:767–9.; Ghannoum M.A., Chen A., Buhari M. et al. Differential in vitro activity of anidulafungin, caspofungin and micafungin against Candida parapsilosis isolates recovered from a burn unit. Clin Microbiol Infect 2009;15:274–9.; Wiederhold N.P., Graybill J.R., Najvar L.K., Burgess D.S. In vitro pharmacodynamics of anidulafungin (afg) and caspofungin (cfg) against clinical isolates of Candida glabrata including strains with elevated MICs to cfg. Abstract presented at the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, December 16–19, 2005.; Ernst E.J., Roling E.E., Petzold C.R. et al. In vitro activity of micafungin (FK-463) against Candida spp.: microdilution, timekill, and postantifungal-effect studies. Antimicrob Agents Chemother 2002;46:3846–53.; Cota J., Carden M., Graybill J.R. et al. In vitro pharmacodynamics of anidulafungin and caspofungin against Candida glabrata isolates, including strains with decreased caspofungin susceptibility. Antimicrob Agents Chemother 2006;50:3926–8.; Canton E., Peman J., Valentin A. et al. In vitro activities of echinocandins against Candida krusei determined by three methods: MIC and minimal fungicidal concentration measurements and timekill studies. Antimicrob Agents Chemother 2009;53:3108–11.; Pound M.W., Townsend M.L., Drew R.H. Echinocandin pharmacodynamics: review and clinical implications. J Antimicrob Chemother 2010;65:1108–18.; Ernst E.J., Klepser M.E., Pfaller M.A. Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neojormans. Antimicrob Agents Chemother 2000;44:1108–11.; Jacobson M.J., Piper K.E., Nguyen G. et al. In vitro activity of anidulafungin against Candida albicans biofilms. Antimicrob Agents Chemother 2008;52:2242–3.; Dannaoui E., Desnos-Ollivier M., Garcia-Hermoso D. et al. Candida spp. with acquired echinocandin resistance, France, 2004–2010. Emerg Infect Dis 2012;18:86–90.; Scudeller L., Viscoli C., Menichetti F. et al. An Italian consensus for invasive candidiasis management (ITALIC). Infection 2014;42:263–79.; Веселов А.В. Прогностические правила для оценки риска инвазивного кандидоза у пациентов ОРИТ. Клиническая микробиология и антимикробная химиотерапия 2017;19(4):296–302.; Moore E., Padiglione A., Wasiak J. et al. Candida in burns: risk factors and outcomes. J Burn Care Res 2010;31(2):257–63.; Lahmer T., Messer M., Mayr U. et al. Fungal “colonization” is associated with increased mortality in medical intensive care unit patients with liver cirrhosis. Mycopathologia 2015;179(1–2):63–71.; Pittet D., Monod M., Suter P.M. et al. Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg 1994;220:751–8.; Ostrosky-Zeichner L., Pappas P., Shoham S. et al. Improvement of a clinical prediction rule for clinical trials on prophylaxis for invasive candidiasis in the in tensive care unit. Mycoses 2011;54:46–51.; Leon C., Ruiz-Santana S., Saavedra P. et al. A bedside scoring system (“Candida score”) for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization. Crit Care Med 2006;34:730–7.; Ostrosky-Zeichner L., Kullberg B.J., Bow E.J. et al. Early treatment of candidemia in adults: a review. Med Mycol 2011;49:113–20.; Диагностика и лечение микозов в отделениях реанимации и интенсивной терапии: Российские рекомендации. Отв. ред. Н.Н. Климко. 2-е изд. доп. и перераб. М.: Фармтек, 2015. 96 с.; Bassetti M., Peghin M., Timsit J.F. The current treatment landscape: candidiasis. J Antimicrob Chemother 2016;71(Suppl 2):ii13–22.; Garey K.W., Rege M., Pai M.P. et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multiinstitutional study. Clin Infect Dis 2006;43:25–31.; Ullmann A., Akova M., Herbrecht R. et al. ESCMID guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). Clin Microbiol Infect 2012;18(Suppl 7):53–67.; https://ok.abvpress.ru/jour/article/view/328

الاتاحة: https://ok.abvpress.ru/jour/article/view/328
https://doi.org/10.17650/2686-9594-2019-9-4-11-20